cancer

Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)

Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)

November 09, 2024 13:00 ET | Source: Replimune Group Inc Oral presentation highlighting IGNYTE primary analysis data shows anti-tumor activity…

6 months ago
Cancer Genetic Risk Assessment Guidelines Expand to Meet Growing Understanding of Hereditary RiskCancer Genetic Risk Assessment Guidelines Expand to Meet Growing Understanding of Hereditary Risk

Cancer Genetic Risk Assessment Guidelines Expand to Meet Growing Understanding of Hereditary Risk

National Comprehensive Cancer Network overhauls two major resources to help cancer care providers and other stakeholders stay current on cutting…

6 months ago
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAMEImmatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME

Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME

 Two oral presentations and multiple posters on clinical andpreclinical-stage candidates to be presented at SITC, demonstratingthe strength of Immatics’ TCR-T…

6 months ago
Cancer Genetic Risk Assessment Guidelines Expand to Meet Growing Understanding of Hereditary RiskCancer Genetic Risk Assessment Guidelines Expand to Meet Growing Understanding of Hereditary Risk

Cancer Genetic Risk Assessment Guidelines Expand to Meet Growing Understanding of Hereditary Risk

National Comprehensive Cancer Network overhauls two major resources to help cancer care providers and other stakeholders stay current on cutting…

6 months ago
Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual MeetingCompass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

New data showed a correlation between the levels of neural cell adhesion molecule (NCAM or CD56) expression and response and…

6 months ago
Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

November 08, 2024 10:00 ET | Source: Medicenna Therapeutics Corp.    MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” BiSKIT…

6 months ago
Cancer Genetic Risk Assessment Guidelines Expand to Meet Growing Understanding of Hereditary RiskCancer Genetic Risk Assessment Guidelines Expand to Meet Growing Understanding of Hereditary Risk

Cancer Genetic Risk Assessment Guidelines Expand to Meet Growing Understanding of Hereditary Risk

National Comprehensive Cancer Network overhauls two major resources to help cancer care providers and other stakeholders stay current on cutting…

6 months ago
Cancer Genetic Risk Assessment Guidelines Expand to Meet Growing Understanding of Hereditary RiskCancer Genetic Risk Assessment Guidelines Expand to Meet Growing Understanding of Hereditary Risk

Cancer Genetic Risk Assessment Guidelines Expand to Meet Growing Understanding of Hereditary Risk

National Comprehensive Cancer Network overhauls two major resources to help cancer care providers and other stakeholders stay current on cutting…

6 months ago
Cancer Genetic Risk Assessment Guidelines Expand to Meet Growing Understanding of Hereditary RiskCancer Genetic Risk Assessment Guidelines Expand to Meet Growing Understanding of Hereditary Risk

Cancer Genetic Risk Assessment Guidelines Expand to Meet Growing Understanding of Hereditary Risk

National Comprehensive Cancer Network overhauls two major resources to help cancer care providers and other stakeholders stay current on cutting…

6 months ago
Sonrai Accelerates Cancer Therapeutics Research with Advanced AnalyticsSonrai Accelerates Cancer Therapeutics Research with Advanced Analytics

Sonrai Accelerates Cancer Therapeutics Research with Advanced Analytics

BELFAST, Northern Ireland, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Sonrai Analytics (Sonrai), an AI precision medicine company providing advanced analytics…

6 months ago
Show more Posts
Show previous Posts